

ASX Release


EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

EMVISION COMPLETES FIRST CLINICAL UNIT TARGETING STROKE DIAGNOSIS

EMVision Medical Devices Limited (ASX: EMV) (“EMVision” or the “Company”) a medical device company focused on the development and commercialisation of medical imaging technology, is pleased to announce that fabrication and assembly of the Company’s first portable brain scanner for its clinical trial is now complete.

“We are thrilled to complete our first clinical unit build and to deliver it to the PA hospital shortly. The EMVision device represents a breakthrough opportunity for imaging the brain, at the point of care, in a manner otherwise not possible today. Our ICU and Neurology clinical collaborators are very excited to start the trial as soon as possible.” said Dr Ron Weinberger, CEO of EMVision.

The device is undergoing internal calibration, verification and electromagnetic compatibility testing in preparation for delivery to Brisbane’s Princess Alexandra Hospital in November. Clinicians and nursing staff will also begin training in the device’s operation and safety before the trial commences.



Head of Technology Development Dr Konstanty Bialkowski alongside the EMVision clinical unit with CEO Dr Ron Weinberger



The EMVision brain scanner pictured alongside a conventional ultrasound device, demonstrating the size and bedside accessibility of the Company's first clinical unit

A further two units will be completed and undergo internal calibration and verification in the next four weeks along with the fabrication of four complete part sets. This will ensure the in-hospital trial is well supported and ongoing commercial device development can continue in parallel to the trial.

The scanner has global applicability, with the potential to generate significant revenue whilst tackling a major health burden. EMVision's pilot-clinical trial remains on track to commence in Q4 CY19 at the Princess Alexandra Hospital in Brisbane.

[ENDS]

For further information, media or investor enquiries, please contact:

Michael Wills
Investor & Media Relations
+61 468 385 208
michael@spring-communications.com.au

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$2 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-

developed the company's platform technology and launched their breakthrough product 'Tropon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.